Recent Finacing
Recent Raise
Cleveland Diagnostics develops SIA-based protein-structure tests, offering IsoPSA as a CLIA-certified LDT that stratifies prostate cancer risk, reduces unnecessary biopsies, and expands into breast and lung.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Cleveland Diagnostics.
